JENBURKT PHARMACEUTICALS LTD.

Jenburkt Pharmaceuticals Ltd has announced the shifting of its registered office within the local limits of Mumbai. The move, approved by the Board of Directors via a circular resolution on July 13, 2026, is effective from July 21, 2026. The new address is 14th floor, Unicorn, Dattaji Salvi Marg, off Veera Desai Road, Andheri West, Mumbai- 400 053, relocating from Nirmala Apartments, 93, Jay Prakash Road, Andheri West, Mumbai 400 058. The company has confirmed that there is no change in the Registrar of Companies (ROC) jurisdiction, and contact details like telephone number, email, and website remain the same.

Jenburkt Pharmaceuticals Limited has announced the closure of its trading window for all designated persons, insiders, and connected individuals, including their relatives. This closure is in effect from July 1, 2026, and will remain open 48 hours after the dissemination of the standalone unaudited financial results for the quarter ending June 30, 2026. The company will separately inform the exchange about the board meeting schedule to consider these financial results.

Jenburkt Pharmaceuticals Ltd has fixed Friday, August 28, 2026, as the record date for payment of dividend for the financial year 2025-26, subject to declaration at the AGM scheduled for September 4, 2026. The dividend will be paid within 30 days of the AGM. The same date is also the cut-off for determining shareholder eligibility for remote e-voting during the AGM.

Jenburkt Pharmaceuticals Ltd's Board of Directors has recommended a dividend of ₹20.70 (207%) per equity share of ₹10 each on 4413300 equity shares for the financial year 2025-26. The board also approved the standalone audited financial statements for the quarter and year ended March 31, 2026, and scheduled the 41st Annual General Meeting for September 4, 2026, via video conferencing. Additionally, Shri Dilip H. Bhuta was re-appointed as the Whole Time Director and CFO for five years, effective April 1, 2027.

Jenburkt Pharmaceuticals Ltd's board re-appointed Shri Dilip H. Bhuta as the Whole Time Director and CFO for five years, effective April 1, 2027, until March 31, 2032, subject to member approval at the 41st Annual General Meeting. The board also approved a dividend of ₹20.70 per equity share for FY26. The 41st AGM is scheduled for September 4, 2026, via video conferencing. Standalone audited financial results for the quarter and year ended March 31, 2026, were approved, showing a revenue from operations of ₹16,874.06 Lacs for the year.

Jenburkt Pharmaceuticals Ltd's standalone audited financial results for the year ended March 31, 2026, show a revenue from operations of ₹16874.06 Lacs, an increase from ₹15169.15 Lacs in the previous year. The company's Board of Directors approved a dividend of ₹220.70 per equity share. Shri Dilip H. Bhuta was re-appointed as the Whole Time Director and CFO for five years, effective April 1, 2027. The 41st Annual General Meeting is scheduled for September 4, 2026, via video conferencing.

Jenburkt Pharmaceuticals Ltd's board approved the standalone audited financial statements for the year ended March 31, 2026. The company reported revenue from operations of ₹168.74 Cr and a profit after tax of ₹34.73 Cr. A dividend of ₹220.70 (207%) per equity share of ₹10 each was declared. The 41st Annual General Meeting is scheduled for September 4, 2026, via video conferencing. Shri Dilip H. Bhuta was re-appointed as the Whole Time Director and CFO for five years effective April 1, 2027.

Jenburkt Pharmaceuticals Ltd has announced that its Board of Directors will convene a meeting on Tuesday, May 5, 2026. The primary agenda items for this meeting include taking on record the audited financial results for the quarter and the full financial year ended March 31, 2026. Additionally, the Board will consider and potentially recommend a dividend for the financial year, if any.

Jenburkt Pharmaceuticals Limited has announced the closure of the trading window for all designated persons, insiders, and connected persons, including their relatives, as per the SEBI(Prohibition of Insider Trading) Regulations, 2015. The closure will be in effect from 1st April, 2026, until 48 hours after the standalone audited financial results for the quarter and financial year ending on 31st March, 2026, are disseminated or made public. The Company will inform the exchange about the schedule of the Board Meeting for considering the said audited financial results separately.

Jenburkt Pharmaceuticals Ltd has reported its standalone unaudited financial results for the quarter and nine months ended on 31st December, 2025. The company's revenue from operations for the quarter is Rs. 15,160.15 lacs and for the nine months is Rs. 11,548.54 lacs. The profit before tax for the quarter is Rs. 1,433.20 lacs and for the nine months is Rs. 3,209.74 lacs. The profit after tax for the quarter is Rs. 1,016.34 lacs and for the nine months is Rs. 2,352.40 lacs. The company has made an additional provision in Employee Benefit Expense in compliance with the new Labour Codes on Wages 2019.